About NPS Pharmaceuticals (NASDAQ:NPSP)
NPS Pharmaceuticals, Inc. (NPS) is a biopharmaceutical company focused on delivering therapies that transform the lives of patients with rare diseases. The Company's primary product Gattex 0.05 mg/kg/d (teduglutide [rDNA origin]) for injection, for subcutaneous use was approved the United States Food and Drug Administration (FDA) for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. The Company's second principal product, Natpara (recombinant human parathyroid hormone 1-84 [rDNA origin] injection, has been developed for hypoparathyroidism, a rare multidimensional disorder characterized by deficient or absent parathyroid hormone (PTH). The Company has collaborations or royalty agreements with Amgen, Janssen, GlaxoSmithKline and Kyowa Hakko Kirin.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biotechnology
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:NPSP
- CUSIP: 62936P10
- Web: N/A
- 50 Day Moving Avg: $46.00
- 200 Day Moving Avg: $34.00
- 52 Week Range: $22.00 - $46.00
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 23.00
- P/E Growth: 0
- Average Volume: 4.38 million shs.
Frequently Asked Questions for NPS Pharmaceuticals (NASDAQ:NPSP)
What is NPS Pharmaceuticals' stock symbol?
NPS Pharmaceuticals trades on the NASDAQ under the ticker symbol "NPSP."
How were NPS Pharmaceuticals' earnings last quarter?
NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) released its quarterly earnings data on Wednesday, February, 18th. The company reported ($0.02) earnings per share for the quarter, missing the consensus estimate of $0.06 by $0.08. The firm had revenue of $66.70 million for the quarter, compared to analysts' expectations of $69.30 million. View NPS Pharmaceuticals' Earnings History.
Who are some of NPS Pharmaceuticals' key competitors?
Some companies that are related to NPS Pharmaceuticals include Amgen (AMGN), Celgene (CELG), Gilead Sciences (GILD), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals Incorporated (VRTX), Grifols SA, Barcelona (GRFS), Incyte (INCY), Illumina (ILMN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Seattle Genetics (SGEN), Jazz Pharmaceuticals plc - (JAZZ), TESARO (TSRO), Alnylam Pharmaceuticals (ALNY), Exelixis (EXEL), BIO-TECHNE Corp (TECH) and Kite Pharma (KITE).
How do I buy NPS Pharmaceuticals stock?
Shares of NPS Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of NPS Pharmaceuticals stock cost?
One share of NPS Pharmaceuticals stock can currently be purchased for approximately $46.00.
Consensus Ratings for NPS Pharmaceuticals (NASDAQ:NPSP) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for NPS Pharmaceuticals (NASDAQ:NPSP)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for NPS Pharmaceuticals (NASDAQ:NPSP)Earnings History by Quarter for NPS Pharmaceuticals (NASDAQ:NPSP)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|2/18/2015||Q414||$0.06||($0.02)||$69.30 million||$66.70 million||View||N/A|
|11/10/2014||Q314||$0.01||($0.02)||$59.50 million||$57.20 million||View||N/A|
|8/6/2014||Q214||($0.01)||$0.02||$53.06 million||$56.10 million||View||Listen|
|5/8/2014||Q114||($0.04)||($0.06)||$48.30 million||$44.04 million||View||Listen|
|2/18/2014||Q413||$0.02||$0.07||$44.22 million||$54.45 million||View||Listen|
|8/8/2013||Q2 2013||($0.07)||($0.13)||$31.62 million||$36.50 million||View||Listen|
|5/9/2013||Q1 2013||($0.13)||($0.09)||$27.56 million||$25.43 million||View||Listen|
|2/21/2013||Q4 2012||($0.09)||($0.14)||$28.93 million||$27.10 million||View||Listen|
|11/9/2012||Q312||($0.16)||($0.04)||$28.18 million||$27.02 million||View||N/A|
Earnings Estimates for NPS Pharmaceuticals (NASDAQ:NPSP)
Current Year EPS Consensus Estimate: $1 EPS
Next Year EPS Consensus Estimate: $2 EPS
Dividend History for NPS Pharmaceuticals (NASDAQ:NPSP)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for NPS Pharmaceuticals (NASDAQ:NPSP)Insider Trades by Quarter for NPS Pharmaceuticals (NASDAQ:NPSP)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|2/10/2015||Susan E Graf||VP||Sell||6,711||$45.87||$307,833.57|| |
|12/17/2014||Joseph J Rogus||SVP||Sell||16,467||$35.00||$576,345.00|| |
|12/17/2014||Luke M Beshar||CFO||Sell||52,258||$35.00||$1,829,030.00|| |
|12/17/2014||Rachel R Selisker||Director||Sell||3,708||$34.59||$128,259.72|| |
|12/8/2014||Rachel R Selisker||Director||Sell||23,157||$34.50||$798,916.50|| |
|11/28/2014||Rachel R Selisker||Director||Sell||11,635||$34.50||$401,407.50|| |
|11/17/2014||Joseph J Rogus||SVP||Sell||26,782||$30.00||$803,460.00|| |
|11/11/2014||Rachel R Selisker||Director||Sell||15,188||$29.50||$448,046.00|| |
|10/31/2014||Luke M Beshar||CFO||Sell||10,000||$29.00||$290,000.00|| |
|10/27/2014||Luke M Beshar||CFO||Sell||30,635||$26.75||$819,486.25|| |
|2/13/2014||Georges Gemayel||Director||Sell||6,188||$37.70||$233,287.60|| |
|1/8/2014||Luke Beshar||CFO||Sell||31,588||$35.01||$1,105,895.88|| |
|12/26/2013||Luke Beshar||CFO||Sell||37,874||$30.02||$1,136,977.48|| |
|12/23/2013||James Groninger||Director||Sell||3,000||$29.50||$88,500.00|| |
|12/18/2013||Ed Stratemeier||SVP||Sell||205,432||$25.13||$5,162,506.16|| |
|9/20/2013||Luke Beshar||CFO||Sell||50,000||$30.26||$1,513,000.00|| |
|9/16/2013||Joseph Rogus||VP||Sell||25,312||$28.11||$711,520.32|| |
|9/16/2013||Luke Beshar||CFO||Sell||50,000||$27.89||$1,394,500.00|| |
|8/30/2013||Roger Garceau||CMO||Sell||110,000||$25.18||$2,769,800.00|| |
|8/20/2013||James Groninger||Director||Sell||16,900||$23.21||$392,249.00|| |
|5/9/2013||Luke M Beshar||CFO||Sell||45,150||$14.18||$640,227.00|| |
|11/15/2012||Glenn R Melrose||SVP||Buy||11,000||$9.09||$99,990.00|| |
|10/3/2012||Roger Garceau||CMO||Sell||140,625||$9.51||$1,337,343.75|| |
Headline Trends for NPS Pharmaceuticals (NASDAQ:NPSP)
Latest Headlines for NPS Pharmaceuticals (NASDAQ:NPSP)
NPS Pharmaceuticals (NPSP) Chart for Monday, May, 22, 2017